| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 110.0 | 231.1 |
| Profit before tax | -36.4 | 57.6 |
| Net income | -32.7 | 51.2 |
| EPS (diluted, $ a share) | $-0.64 | $0.91 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -52.4% |
|---|---|
| Operating margin | -33.9% |
10-Q filed with the SEC, NYSE: EBS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Emergent BioSolutions Inc.: key numbers
- Share price
- $5.81Close, Nov 16
- Market cap
- $299M
- Shares outstanding
- 51.42MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Emergent BioSolutions Inc.
All →Emergent BioSolutions Wins $22.3M Contract from U.S. Department of War
Emergent BioSolutions received a $22.3 million modification exercising an option under an existing IDIQ contract to supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of War. Deliveries will begin in 2026 with a $7.4 million initial shipment and continue through 2027 to support anthrax pre-exposure prophylaxis for all branches of the U.S. military.
- Value
- $22.3M
- Counterparty
- U.S. Department of War
- Term
- through 2027
Emergent BioSolutions Financial Results
Emergent BioSolutions reported Q3 2026 total revenues of $110.0 million, a 52% decrease year-over-year, and a net loss of $32.7 million. The results were primarily driven by the company's biodefense and naloxone portfolios as it continues a multi-year strategic transformation and turnaround.
- Term
- Q3 2026
“Emergent's third-quarter results, which include revenue of $110.0 million inline with our guidance, were primarily driven by our diverse biodefense/medical countermeasures and naloxone portfolio, underscoring the importance of disciplined execution as we advance our multi-year transformation.”
Joe Papa, president and chief executive officer
“We remain focused on our turnaround priorities and strengthening our financial position, which includes improving operating performance, reducing debt, creating long-term shareholder value, continuously demonstrating high standards of quality and compliance in all we do and delivering on our mission to protect and save lives.”
Joe Papa, president and chief executive officer
Emergent BioSolutions Leadership Change
Richard Lindahl will retire as CFO of Emergent BioSolutions effective December 31, 2026, remaining as an advisor through March 2027. Frank Vargo, the company's current VP and Treasurer, has been appointed Interim CFO effective January 1, 2027.
Emergent BioSolutions Insider Donald W. DeGolyer Sells $126K of Stock
Donald W. DeGolyer sold 17,800 shares of Emergent BioSolutions Inc. at $7.09 a share, worth $126K in total on Oct 7, 2026. Shares held after the trade: 111,921 (-13.7%).
- Value
- $126K
- Shares
- 17,800
- Price
- $7.09
- Holding change
- -13.7%
- Trade date
- Oct 7, 2026
Emergent BioSolutions SVP, Products Business Paul Anthony Williams Sells $19.6K of Stock
Paul Anthony Williams, SVP, Products Business, sold 3,000 shares of Emergent BioSolutions Inc. at $6.53 a share, worth $19.6K in total on Oct 1, 2026. Shares held after the trade: 156,098 (-1.9%).
- Value
- $19.6K
- Shares
- 3,000
- Price
- $6.53
- Role
- SVP, Products Business
- Holding change
- -1.9%
- Trade date
- Oct 1, 2026
Emergent BioSolutions Investor Presentation
Emergent BioSolutions CEO Joseph C. Papa is presenting at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company filed a formal investor presentation deck as an exhibit, which outlines its strategy for combating public health threats and provides updates on its medical countermeasure portfolio, including CYFENDUS and NARCAN.
- Counterparty
- H.C. Wainwright